Pharma
Commented by Juliane Zielonka on September 2nd, 2024 | 07:55 CEST
Globex Mining, Bayer, and Plug Power - Which company offers the best return with low risk?
Investors understand the interplay between risk and return. Which sectors offer high returns? The Canadian commodities company Globex Mining skillfully balances risk and return in the commodities sector with its diversified portfolio of over 200 commodities projects in North America and Europe. Its setup is akin to a mini-version of Berkshire Hathaway. Bayer AG is tapping into new growth opportunities in the pharmaceuticals sector with its Phase III study for a lung cancer drug. This is much needed as numerous patents are expiring. Plug Power, a pioneer in hydrogen technology is putting all its eggs in one basket - with the potential for huge profits but also considerable losses, as evidenced by the share price plunge from USD 70 in 2021 to currently below USD 3 shows. Which company offers the best return with low risk?
Read
Commented by Stefan Feulner on August 28th, 2024 | 07:15 CEST
Siemens Healthineers, Vidac Pharma, Viking Therapeutics - Powerful movements
After the hype during the COVID-19 pandemic, biotech stocks have lagged behind the broader market, allowing major technology companies to take the lead. Smaller, capital-intensive companies, in particular, have suffered from the high interest rate level. However, this is likely to change soon. On the one hand, monetary policy is expected to be eased, and on the other hand, demographic changes point to a long-term explosion in demand for new medications.
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by Juliane Zielonka on August 9th, 2024 | 06:30 CEST
Cardiol Therapeutics, Novo Nordisk, Bayer - Pharma stocks in focus
The healthcare sector promises further blockbusters for investors. Cardiol Therapeutics impresses with its promising Phase II study of CardiolRx™ for the treatment of the heart disease pericarditis. The growing market for pericarditis treatments offers the Company great potential, which has also been positively noted by analysts. The Danish company Novo Nordisk is experiencing impressive growth thanks to its GLP-1-based diabetes and obesity drugs. The active ingredient is causing a stir in the celebrity scene as an off-label weight loss injection, further boosting the Company's sales figures. Bayer AG is facing up to its challenges. Despite slight revenue growth in the second quarter of 2024, profits declined. Nevertheless, CEO Bill Anderson believes the Company is on the right track, particularly thanks to progress in the pharmaceutical pipeline. We have three companies in focus.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Juliane Zielonka on August 2nd, 2024 | 06:30 CEST
Transformation in full swing: Altech, Volkswagen, and Bayer focus on new technologies and markets
Shortly after the grandiose Olympic opening ceremony, Paris showed us what it means to sit in the dark. One day after the opening ceremony, the inhabitants of the Seine were hit by a power outage. Speculation as to the cause ranges from a cyber attack to sabotage, similar to the recent arson attacks on the French rail network. But one thing is certain, it shows how fragile the power supply currently is. This is reason enough for Altech Advanced Materials to press ahead with the development of its stationary solid-state battery. A type of local battery power plant ensures a stable power supply, even with fluctuations in the grid due to wind and solar energy. The German company has another profitable development up its sleeve for the EV market. Volkswagen continues to focus on its electric vehicles and can look forward to increased sales in China. Nevertheless, the Wolfsburg-based company must make considerable savings to remain profitable. The results of the first half of the year provide deep insights. Additionally, for 27 million women in the US, ones battery can be figuratively "empty" at times. Fatigue, hot flashes, and nervousness are classic symptoms of menopause. 27 million is the market size of menopausal women that Bayer AG now aims to capture with a very special medication...
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read
Commented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
Read
Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST
BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?
On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.
Read